Case Study: How AstraZeneca evolved its digital supply chainGiving people the tools to do their job more effectively has boosted productivity at AstraZeneca. The company says Share XCase Study: How AstraZeneca evolved its digital supply chainhttps://pharmaphorum.com/debates-insight-sales-marketing/case-study-how-astrazeneca-evolved-its-digital-supply-chain/
AZ’s CEO dismisses “fake news” about his imminent departureAstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced Share XAZ’s CEO dismisses “fake news” about his imminent departurehttps://pharmaphorum.com/news/azs-ceo-dismisses-fake-news-about-his-imminent-departure/
AZ’s lung drug gets fast development in EU and USRegulators in the US and Europe have fast-tracked development of AstraZeneca’s MEDI8897, an antibody drug aimed at preventing Share XAZ’s lung drug gets fast development in EU and UShttps://pharmaphorum.com/news/us-and-eu-accelerate-medi8897/
Europe’s CHMP recommends AZ’s Forxiga in type 1 diabetesThe European Medicines Agency’s CHMP regulatory committee has recommended AstraZeneca’s Forxiga to help adults with type 1 diabetes Share XEurope’s CHMP recommends AZ’s Forxiga in type 1 diabeteshttps://pharmaphorum.com/news/europes-chmp-recommends-azs-forxiga-in-type-1-diabetes/
Sobi buys AstraZeneca’s RSV virus drug for $1.5bnSobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain Share XSobi buys AstraZeneca’s RSV virus drug for $1.5bnhttps://pharmaphorum.com/news/sobi-buys-astrazenecas-rsv-virus-drug-for-1-5bn/
Women in Science: AstraZenecaWe speak to three of AstraZeneca’s senior leaders about their careers, the future of their therapy areas and Share XWomen in Science: AstraZenecahttps://pharmaphorum.com/r-d/views-analysis-r-d/women-in-science-astrazeneca/
AZ’s chief medical officer Bohen quits after shake-upAstraZeneca’s chief medical officer Sean Bohen is to leave the company following its organisational shake-up. This is the Share XAZ’s chief medical officer Bohen quits after shake-uphttps://pharmaphorum.com/news/azs-chief-medical-officer-bohen-quits-after-shake-up/
AZ appoints controversial doctor to lead new oncology unitAstraZeneca has a new and controversial oncology head after the departure of two key leaders led to a Share XAZ appoints controversial doctor to lead new oncology unithttps://pharmaphorum.com/news/az-appoints-controversial-doctor-to-lead-new-oncology-unit/
NICE broadens approval for AstraZeneca’s severe asthma drugAstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – Share XNICE broadens approval for AstraZeneca’s severe asthma drughttps://pharmaphorum.com/news/nice-broadens-approval-for-astrazenecas-severe-asthma-drug/
